Trimetazidine improves endothelial dysfunction in chronic heart failure: an antioxidant effect.

Aims: To determine whether trimetazidine (TMZ) improves the endothelium-dependent relaxation (EDR) in chronic heart failure (CHF) and whether this effect is associated with its antioxidant properties.

Methods And Results: We studied 51 patients (mean age 51.4 +/- 6 years) with CHF secondary to ischaemic cardiomyopathy (ejection fraction 32.

Coenzyme Q10 and exercise training in chronic heart failure.

Aims: There is evidence that plasma coenzyme Q(10) (CoQ(10)) levels decrease in patients with advanced chronic heart failure (CHF). However, it is not known whether oral CoQ(10) supplementation may improve cardiocirculatory efficiency and endothelial function in patients with CHF.

Methods And Results: We studied 23 patients in NYHA class II and III (20 men, three women, mean age 59+/-9 years) with stable CHF secondary to ischaemic heart disease [ejection fraction 37+/-7%], using a double-blind, placebo-controlled cross-over design.

Coenzyme Q10 improves contractility of dysfunctional myocardium in chronic heart failure.

Background: There is evidence that plasma CoQ(10) levels decrease in patients with advanced chronic heart failure (CHF).

Objective: To investigate whether oral CoQ(10) supplementation could improve cardiocirculatory efficiency in patients with CHF.

Methods: We studied 21 patients in NYHA class II and III (18M, 3W, mean age 59 +/- 9 years) with stable CHF secondary to ischemic heart disease (ejection fraction 37 +/- 7%), using a double-blind, placebo-controlled cross-over design.